News & Updates

Show Multimedia Only

First-line atezolizumab plus CP/ET offers survival benefits in ES-SCLC

30 May 2025 by

Patients with extensive-stage small cell lung cancer (ES-SCLC) derive real-world clinical benefits from first-line treatment with atezolizumab combined with carboplatin and etoposide (CP/ET), reports a recent study.

First-line atezolizumab plus CP/ET offers survival benefits in ES-SCLC

30 May 2025

Original-New-Drug-Application-Approvals-by-US-FDA--1-15-May-2025

29 May 2025

New drug applications approved by US FDA as of 1-15 May 2025 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original-New-Drug-Application-Approvals-by-US-FDA--1-15-May-2025

29 May 2025

Adolescent fitness lowers cancer risk in adulthood

28 May 2025 by

High cardiorespiratory fitness during adolescence appears to provide protection against cancer development and death in late adulthood, suggests a study. This finding is consistent in sibling comparisons.

Adolescent fitness lowers cancer risk in adulthood

28 May 2025

Multiple skin cancers can occur in treated patients, says study

28 May 2025

A recent study claims that almost half of the patients treated for skin cancer will again develop the disease within 2 years of the first incidence.

Multiple skin cancers can occur in treated patients, says study

28 May 2025

Antiviral therapy lowers HCC risk in indeterminate CHB phase

27 May 2025 by

Patients with chronic hepatitis B (CHB) in the indeterminate phase are predisposed to advanced liver disease and hepatocellular carcinoma (HCC), as shown by a systematic review and meta-analysis.

Antiviral therapy lowers HCC risk in indeterminate CHB phase

27 May 2025

Personalizing upfront treatment options for advanced EGFRm NSCLC

26 May 2025 by

This article will summarize the latest developments in the first-line management of advanced EGFRm NSCLC and highlight key consideration factors.

Personalizing upfront treatment options for advanced EGFRm NSCLC

26 May 2025

No APHINITY between statin use and survival outcomes in early HER2-positive breast cancer

26 May 2025 by

Statin use was not associated with improved survival outcomes in the phase III APHINITY trial investigating the addition of pertuzumab to trastuzumab and chemotherapy as adjuvant treatment for patients with early HER2-positive breast cancer (BC).

No APHINITY between statin use and survival outcomes in early HER2-positive breast cancer

26 May 2025

Next-generation KRASG12C inhibitor monotherapy convenient, shows promising antitumour activity

25 May 2025 by

A multinational phase I study led by the Chinese University of Hong Kong (CUHK) reports an overall objective response rate (ORR) of >70 percent in advanced solid KRAS^G12C-mutant tumours treated with D3S-001, a next-generation KRAS^G12C inhibitor developed in mainland China.

Next-generation KRASG12C inhibitor monotherapy convenient, shows promising antitumour activity

25 May 2025

GLP-1RAs help reduce risk of gastrointestinal cancers

23 May 2025 by

Treatment with glucagon-like peptide-1 receptor agonists (GLP-1RAs), as opposed to insulin or metformin, provides a protective benefit against the development of gastrointestinal cancers, as shown in a study presented at DDW 2025.

GLP-1RAs help reduce risk of gastrointestinal cancers

23 May 2025

Dostarlimab may eliminate the need for surgery in early-stage dMMR tumours

23 May 2025 by

PD-1 blockade with dostarlimab may eliminate the need for surgery in patients with early-stage mismatch repair–deficient (dMMR) solid tumours amenable to curative intent surgery, a phase II trial has shown.

Dostarlimab may eliminate the need for surgery in early-stage dMMR tumours

23 May 2025

News & Updates

Showing Oncology articles

Showing

Specialty:

First-line atezolizumab plus CP/ET offers survival benefits in ES-SCLC

First-line atezolizumab plus CP/ET offers survival benefits in ES-SCLC

Original-New-Drug-Application-Approvals-by-US-FDA--1-15-May-2025

Original-New-Drug-Application-Approvals-by-US-FDA--1-15-May-2025

Adolescent fitness lowers cancer risk in adulthood

Adolescent fitness lowers cancer risk in adulthood

Multiple skin cancers can occur in treated patients, says study

Multiple skin cancers can occur in treated patients, says study

Antiviral therapy lowers HCC risk in indeterminate CHB phase

Antiviral therapy lowers HCC risk in indeterminate CHB phase

Personalizing upfront treatment options for advanced EGFRm NSCLC

Personalizing upfront treatment options for advanced EGFRm NSCLC

No APHINITY between statin use and survival outcomes in early HER2-positive breast cancer

No APHINITY between statin use and survival outcomes in early HER2-positive breast cancer

Next-generation KRASG12C inhibitor monotherapy convenient, shows promising antitumour activity

Next-generation KRASG12C inhibitor monotherapy convenient, shows promising antitumour activity

GLP-1RAs help reduce risk of gastrointestinal cancers

GLP-1RAs help reduce risk of gastrointestinal cancers

Dostarlimab may eliminate the need for surgery in early-stage dMMR tumours

Dostarlimab may eliminate the need for surgery in early-stage dMMR tumours